reports
Pharmena S.A.: 1 director sold
A director at Pharmena S.A. sold 22,700 shares at 9.860PLN and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sh...
- Adrian Kowollik
- Adrian Kowollik
- Adrian Kowollik
- Adrian Kowollik
- Adrian Kowollik
Update on the Polish dermocosmetics and biotech company PHARMENA S.A.
PHARMENA is a Polish company, which has developed the patented 1-MNA substance. It offers dermocosmetics and is working on a 1-MNA dietary supplement as well as a 1-MNA drug. The drug completed Phase II of clinical research in 2016. ​
Ford Equity International Rating and Forecast Report
Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind...
PHARMENA S.A. - Update after results of Phase II clinical study
Our updated SOTP model, which accounts for the latest news flow, derives a 12-months fair value for the stock of PLN 28.80 vs. PLN 32 before. Although its results in 2016 will be lower than we had previously forecast, the dermocosmetics & dietary supplement segment will benefit from the introduction of 50 new products until 2017E and distribution agreements e.g. in the Middle East and South Korea. While results of the Phase II study relating to the ability of the 1-MNA drug to reduce triglycerid...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.